Oracle says CROs AMS Advanced Medical Services GmbH, Firma Clinical and EPS have signed up to use its cloud-based clinical trial management platform.
The firm announced the new contracts last week, explaining that through the 12-month deals contract research organization's (CROs) can evaluate, familiarize and train with the technology – known as Clinical One – in addition to being able to demonstrate it to potential sponsors.
According to Oracle the platform harmonizes data, streamlines workflow and saves significant time from study startup to study closeout. The firm also claimed It gives CROs and sponsors easy access to the data needed to support critical decision-making, patient safety, and study oversight.
Seema Verma, executive vice president and general manager, Oracle Health and Oracle Life Sciences suggested the cost pressures were a factor in the new contracts.
“As the demand continues to grow and the expectation of faster, lower-cost trials accelerates, CROs are under greater pressure to deliver measurable results quickly.
“We created the CRO Growth Initiative to provide CROs the ability to use industry-leading technology to meet the needs of their clients with greater efficiency, speed, and accuracy” Verma said.
Hassan Kazerooni, director, data management, AMS Advanced Medical Services GmbH, also cited customer demand as a major factor in the new contract.
“Working with Oracle through the CRO Growth Initiative has allowed us to expand our offering with Clinical One to offer the best technology options that match the needs of our customers for international clinical studies,” Kazerooni said.
For Lisa Squibb, associate vice president, data management, Firma Clinical, the contract is about keeping pace with a changing market.
“The opportunity to collaborate using Oracle’s Clinical One provides Firma Clinical the ability to be at the forefront of the ever-changing clinical trial technology environments.”
Oracle launched the technology and the wider “CRO Growth Initiative” two years ago in a bid to expand its presence in the clinical trials space.
DepositPhotos/ra2studio